
Stem cell bank LifeCell raises ₹225 crore
The Hindu
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics.
Stem cell bank and reproductive genetic testing service provider LifeCell International Pvt. Ltd. said that OrbiMed Asia Partners IV has invested ₹225 crore in return for a minority stake.
“We received an equity infusion of ₹225 crore from leading healthcare investment firm OrbiMed Asia Partners IV. The existing founders will invest ₹30 crore,” said Mayur Abhaya, MD.
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics. Besides, it would also enable the company grow its diagnostic division and set up laboratories offering varied kinds of tests.